Potential new treatments for Parkinson’s disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.
In a study published in Nature Communications, Rush researchers found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy bodies are hallmarks of Parkinson’s disease, the most common movement disorder affecting about 1.2 million people in the United States and Canada.
The lab-developed peptides tested in the study are known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD). The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson’s disease. The treatments also improved the mice’s gait, balance, and other motor functions.
Release date: 20 September 2021
Source: Rush University Medical Center